☰
We're an open science community making best practice in antibody choice and use feasible, easy, and rewarding. Led from the University of Leicester and working with 26+ partner organisations across manufacturing, funding, publishing, and research.
Search knockout-validated characterisation data across western blot, immunoprecipitation, immunofluorescence, and flow cytometry. Compare antibodies from 14 manufacturers side by side, with application-specific recommendations. All data generated through our collaboration with YCharOS Inc.
Free, self-paced e-learning covering antibody selection, the five pillars of validation, database navigation, and data interpretation. Five modules with quizzes and a downloadable PDF certificate on completion.
A joint OGA/NC3Rs programme recruiting early career researchers to drive culture change in antibody validation at their own institutions. 12-month programme with professional training from Inspire Change and expert mentorship from AstraZeneca and YCharOS.
Two peer-reviewed preprints published March 2026 — quantifying the ethical and scientific costs of inadequate validation and presenting 15 consensus recommendations from 32 international experts, with action plans for institutions, funders, publishers, and manufacturers.
Identifying robust reagents to study key targets of interest, in collaboration with antibody manufacturers through YCharOS and the NC3Rs. Characterising antibodies across four applications with knockout-validated controls to build a trusted, open dataset.
Driving better standards in antibody choice and use across the research lifecycle — from funding applications through purchasing decisions, experimental design, and manuscript assessment. Developing the database, training resources, and stakeholder engagement tools.
Using well-characterised antibodies to identify proteins that predict treatment responses in interstitial lung disease (ILD) patients — working towards better diagnosis and more targeted treatment selection through robust, reproducible antibody tools.
Our work was featured in Nature Magazine, highlighting OGA's role in the international effort to improve antibody quality and research reproducibility.
Read more →Awarded for contributions to reproducible and open research culture — recognising the OGA community's collaborative approach to tackling the antibody crisis.
Read more →Published as an impact case study by the UK Reproducibility Network, demonstrating how OGA's collaboration with YCharOS supports better biomedical research using antibodies.
Read more →
Co-lead (Clinical)
Co-lead (Molecular Biology)
Co-lead (Behavioural Science)
Characterisation & biomarker project support
PhD student (in collaboration with Abcam Ltd)
Bioinformatics
Partnership manager
OGA is led from the University of Leicester and is an affiliate stakeholder of the UK Reproducibility Network. Our work is supported by the NC3Rs, the MRC-NIHR Better Methods Better Research programme, the Leicester Institute for Precision Health, and the NIHR Leicester Biomedical Research Centre. We are part of the wider movement to improve research integrity and reproducibility, and our work represents an opportunity for learning in the wider context of trustworthy research and reliable diagnostics.